Arrogene, Inc., was founded in 2006, to commercialize both a new targeted cancer treatment technology and a proprietary molecular delivery platform aimed at inhibiting and ultimately stopping, tumor progression. Arrogene has licensed technologies and patents for its core technology–Polycefin™–from Cedars-Sinai Medical Center (CSMC) in Los Angeles, one of the nation’s premiere research institutions. The founders of Arrogene were principally involved in the research and development of Polycefin™–a breakthrough biopolymer-based nano delivery platform, capable of targeted delivery of protein, peptide, small molecule or olignucleotide therapeutics. 

Work on Polycefin™ involved eight years of development and nearly $30 million in grants funded by the National Institutes of Health (NIH) and other foundations. 

Our Partnering Strategy

Arrogene is actively seeking partners in both the U.S. and International markets, including pharmaceutical companies with existing cancer therapy drugs or active diagnostic imaging agents as well as biomarkers, that might benefit from better targeting and reduced toxicity.

Our production laboratory has the know-how to engineer nanoconjugates rapidly and reliably, and support in vitro and in vivo characterization. We have partnered with the Nanotechnology Characterization Laboratory (NCL), the organization created by the National Institute of Standards and Technology (NIST), the U.S. Food and Drug Administration (FDA), and the National Cancer Institute (NCI) to perform preclinical efficacy and toxicity testing of our nanomedicines. NCL has completed the characterization of lead Pol